C-Reactive Protein: The Quintessential Marker of Systemic Inflammation in Coronary Artery Disease-Advancing toward Precision Medicine

被引:64
作者
Amezcua-Castillo, Emanuel [1 ]
Gonzalez-Pacheco, Hector [2 ]
Martin, Arturo Saenz-San [3 ]
Mendez-Ocampo, Pablo [3 ]
Gutierrez-Moctezuma, Ivan [3 ]
Masso, Felipe [4 ]
Sierra-Lara, Daniel [2 ]
Springall, Rashidi [5 ]
Rodriguez, Emma [4 ]
Arias-Mendoza, Alexandra [2 ]
Amezcua-Guerra, Luis M. [5 ,6 ]
机构
[1] Univ Nacl Autonoma Mexico, Escuela Nacl Preparatoria Antonio Caso 6, Mexico City 04100, Mexico
[2] Inst Nacl Cardiol Ignacio Chavez, Coronary Care Unit, Mexico City 14080, Mexico
[3] Univ Autonoma Metropolitana Xochimilco, Sch Med, Mexico City 14387, Mexico
[4] Inst Nacl Cardiol Ignacio Chavez, Translat Res Unit, Mexico City 14080, Mexico
[5] Inst Nacl Cardiol Ignacio Chavez, Dept Immunol, Mexico City 14080, Mexico
[6] Univ Autonoma Metropolitana Xochimilco, Hlth Care Dept, Mexico City 14387, Mexico
关键词
C-reactive protein; coronary artery disease; atherosclerotic cardiovascular disease; inflammation; precision medicine; personalized cardiology; DENSITY-LIPOPROTEIN CHOLESTEROL; GLOBAL CARDIOVASCULAR RISK; STATIN THERAPY; HEART-FAILURE; LIRAGLUTIDE; OUTCOMES; SIMVASTATIN; MECHANISMS; PREDICTION; BIOMARKERS;
D O I
10.3390/biomedicines11092444
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Atherosclerotic cardiovascular disease (CVD) remains the leading cause of mortality worldwide. While conventional risk factors have been studied and managed, CVD continues to pose a global threat. Risk scoring systems based on these factors have been developed to predict acute coronary syndromes and guide therapeutic interventions. However, traditional risk algorithms may not fully capture the complexities of individual patients. Recent research highlights the role of inflammation, particularly chronic low-grade inflammation, in the pathogenesis of coronary artery disease (CAD). C-reactive protein (CRP) is an inflammatory molecule that has demonstrated value as a predictive marker for cardiovascular risk assessment, both independently and in conjunction with other parameters. It has been incorporated into risk assessment algorithms, enhancing risk prediction and guiding therapeutic decisions. Pharmacological interventions with anti-inflammatory properties, such as statins, glucagon-like peptide-1 agonists, and interleukin-1 inhibitors, have shown promising effects in reducing both cardiovascular risks and CRP levels. This manuscript provides a comprehensive review of CRP as a marker of systemic inflammation in CAD. By exploring the current knowledge surrounding CRP and its implications for risk prediction and therapeutic interventions, this review contributes to the advancement of personalized cardiology and the optimization of patient care.
引用
收藏
页数:15
相关论文
共 68 条
[1]   Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[2]   A simple and readily available inflammation-based risk scoring system on admission predicts the need for mechanical ventilation in patients with COVID-19 [J].
Amezcua-Guerra, Luis M. ;
Audelo, Karen ;
Guzman, Juan ;
Santiago, Diana ;
Gonzalez-Flores, Julieta ;
Garcia-Avila, Carlos ;
Torres, Zaira ;
Baranda-Tovar, Francisco ;
Tavera-Alonso, Claudia ;
Sandoval, Julio ;
Gonzalez-Pacheco, Hector .
INFLAMMATION RESEARCH, 2021, 70 (06) :731-742
[3]  
Amezcua-Guerra Luis M, 2007, Arch. Cardiol. Méx., V77, P58
[4]   Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial [J].
Anholm, Christian ;
Kumarathurai, Preman ;
Pedersen, Lene Rorholm ;
Samkani, Amirsalar ;
Walzem, Rosemary L. ;
Nielsen, Olav Wendelboe ;
Kristiansen, Ole Peter ;
Fenger, Mogens ;
Madsbad, Sten ;
Sajadieh, Ahmad ;
Haugaard, Steen Bendix .
ATHEROSCLEROSIS, 2019, 288 :60-66
[5]  
[Anonymous], AM J MED, DOI [10.1016/j.amjmed.2005.06.057, DOI 10.1016/J.AMJMED.2005.06.057]
[6]   Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study [J].
Bacchiega, Bruno Cesar ;
Bacchiega, Ana Beatriz ;
Gomez Usnayo, Magali Justina ;
Bedirian, Ricardo ;
Singh, Gurkirpal ;
Castelar Pinheiro, Geraldo da Rocha .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (03)
[7]   Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight toss [J].
Balducci, S. ;
Zanuso, S. ;
Nicolucci, A. ;
Fernando, F. ;
Cavallo, S. ;
Cardelli, P. ;
Fallucca, S. ;
Alessi, E. ;
Letizia, C. ;
Jimenez, A. ;
Fallucca, F. ;
Pugliese, G. .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2010, 20 (08) :608-617
[8]   Mechanisms of Plaque Formation and Rupture [J].
Bentzon, Jacob Fog ;
Otsuka, Fumiyuki ;
Virmani, Renu ;
Falk, Erling .
CIRCULATION RESEARCH, 2014, 114 (12) :1852-1866
[9]   CRP-Induced NLRP3 Inflammasome Activation Increases LDL Transcytosis Across Endothelial Cells [J].
Bian, Fang ;
Yang, Xiao-Yan ;
Xu, Gao ;
Zheng, Tao ;
Jin, Si .
FRONTIERS IN PHARMACOLOGY, 2019, 10
[10]   Fluctuating inflammatory markers in patients with stable ischemic heart disease [J].
Bogaty, P ;
Brophy, MM ;
Boyer, L ;
Simard, S ;
Joseph, L ;
Bertrand, F ;
Dagenais, GR .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (02) :221-226